News >

Everolimus Shows Efficacy in Combating Endocrine Resistance in Breast Cancer

Jason Harris
Published: Wednesday, Apr 25, 2018

Dr Noah S. Kornblum

Noah S. Kornblum, MD
Everolimus demonstrated strong potential as an effective tool for overcoming endocrine resistance in postmenopausal women with ER-positive, HER2-negative metastatic breast cancer resistant to aromatase inhibitor (AI) therapy.

Results from the PrE0102 trial published in the Journal of Clinical Oncology showed that adding the mTOR inhibitor to fulvestrant (Faslodex) in this patient population resulted in a median progression-free survival (PFS) of 10.3 months compared with 5.1 months for fulvestrant plus placebo (HR, 0.61; 95% CI, 0.40-0.92; stratified log-rank P = .02).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication